Patent intelligence · AU
AU 2022390453
NOVEL HETEROARYL-UREA COMPOUNDS AS KV7.2 INHIBITORS
NOVEL HETEROARYL-UREA COMPOUNDS AS KV7.2 INHIBITORS
Patent details — AU 2022390453
- Jurisdiction
- AU
- Status
- granted
- Grant date
- May 30, 2024
- Expiration
- May 25, 2044
- Applicant
- ANGELINI PHARMA S P A [IT]
- CPC classes
- A61K/3144, A61K/314427, A61K/31443, A61K/314433
Quick answer
AU 2022390453 (NOVEL HETEROARYL-UREA COMPOUNDS AS KV7.2 INHIBITORS) is held by ANGELINI PHARMA S P A [IT]. Status: granted. Granted May 30, 2024. Expires May 25, 2044 (18 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- ANGELINI PHARMA S P A [IT]
- Grant date
- Expiration
- Claims
- —
- CPC classes
- A61K/3144, A61K/314427, A61K/31443, A61K/314433, A61K/314439, A61K/31444
More from ANGELINI PHARMA S P A [IT]
Related pharmaceutical patents in our USPTO index.
-
WO 2025252600
COMPOSÉS ACTIVATEURS DE CANAUX POTASSIQUES KV7.2/KV7.3
granted -
WO 2025252599
COMPOSÉS ACTIVATEURS DE CANAUX POTASSIQUES KV7.2/KV7.3
granted -
AU 2024268154
NOVEL CARBOXAMIDE DERIVATIVES
granted -
IT 202300027246
Matrici farmaceutiche per il rilascio prolungato di farmaci
granted -
IT 202200024948
Composti attivatori dei canali potassio KV7.2/KV7.3
granted -
IT 202200024963
Composti attivatori dei canali potassio Kv7.2/Kv7.3
granted
Frequently asked questions
What is US patent 2022390453?
AU 2022390453 (NOVEL HETEROARYL-UREA COMPOUNDS AS KV7.2 INHIBITORS) is held by ANGELINI PHARMA S P A [IT]. Status: granted. Granted May 30, 2024. Expires May 25, 2044 (18 years remaining) — relevant for patent-cliff and LOE planning.
Who owns AU 2022390453?
ANGELINI PHARMA S P A [IT] is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 7 pharmaceutical patents for this assignee.
When does AU 2022390453 expire?
Our index shows an expiration date of May 25, 2044 (18 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.